19:57 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Zogenix to advance regulatory plans on second Phase III win

Zogenix Inc. (NASDAQ:ZGNX) reported top-line data showing ZX008 as an adjunctive therapy to stiripentol regimen met the primary endpoint in its second Phase III trial, Study 1504, to treat Dravet syndrome. Daily 0.5 mg/kg oral ZX008...
20:34 , Jul 12, 2018 |  BC Extra  |  Clinical News

Zogenix market cap grows with second Phase III win

Zogenix Inc. (NASDAQ:ZGNX) gained $9.60 (21%) to $55.90 on Thursday, adding about $338 million in market cap, after it reported top-line data showing ZX008 as an adjunctive therapy to stiripentol regimen met the primary endpoint...
19:28 , Jul 3, 2018 |  BC Extra  |  Company News

Management tracks: Cigna, Novocure, Voyager

Health services company Cigna Corp. (NYSE:CI) appointed Mark McClellan to its board, effective the earlier of Dec. 1 or the close of Cigna's acquisition of Express Scripts Holding Co. (NASDAQ:ESRX). McClellan is director of the...
01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
16:18 , Feb 9, 2018 |  BC Week In Review  |  Clinical News

FDA grants breakthrough therapy designation to Zogenix's ZX008

Zogenix Inc. (NASDAQ:ZGNX) said FDA granted breakthrough therapy designation to ZX008 to treat seizures associated with Dravet syndrome. The designation is based on data from the Phase III Study 1 to treat Dravet syndrome showing...
16:26 , Jan 12, 2018 |  BC Week In Review  |  Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
23:54 , Jan 9, 2018 |  BC Extra  |  Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
22:06 , Dec 15, 2017 |  BC Week In Review  |  Clinical News

Zogenix reports additional Phase III data for ZX008 in Dravet syndrome

Zogenix Inc. (NASDAQ:ZGNX) reported additional data from the Phase III Study 1 to treat Dravet syndrome showing that once-daily 0.8 mg/kg ZX008 as adjunctive therapy led to a “much improved” or “very much improved” overall...
18:29 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Zogenix's ZX008 meets in Phase III for Dravet syndrome

Zogenix Inc. (NASDAQ:ZGNX) reported top-line data showing that ZX008 as adjunctive therapy met the primary endpoint of reducing mean monthly convulsive seizure frequency in the Phase III Study 1 to treat Dravet syndrome. Top-line data...
17:55 , Oct 6, 2017 |  BC Week In Review  |  Company News

Arcturus, Alcobra merging

RNA medicines company Arcturus Therapeutics Inc. (San Diego, Calif.) will merge with Alcobra Ltd. (NASDAQ:ADHD) in a stock deal expected to close this quarter. Alcobra shareholders will own about 40% of the combined company; Arcturus...